Ceros Financial Services Arranges $17.14 Million Financing of Aquyre Biosciences

MIAMI, Nov. 15, 2021 /PRNewswire/ -- Ceros Capital Markets, a division of Ceros Financial Services, announced that it has, as Placement Agent, completed a $17.14 million Series A2 Preferred Stock financing round for Aquyre Biosciences, a U.S. company which has developed and built a disruptive medical diagnostic platform for on-site adequacy assessment of tissue biopsies. Its CelTivity™ system captures intracellular data from the biopsy and creates Dynamic Cell Images™ of the tissue samples to identify and interpret the presence of different types of cells, such as cancer, non-cancer and granuloma, to name a few. The image acquisition takes less than 2 minutes, while the patient is still present in the procedure suite.

Aquyre's Dynamic Cell Images™ enable the proceduralist to eliminate the uncertainty with intraprocedural tissue adequacy of the entire tissue sample, without staining or sacrificing the biopsy, with accuracy and precision. This increases the probability that enough cells are presented for pathology analysis, while improving diagnostic yield.

Aquyre's technology and its digitized sample holder model will permit biopsy data and results to be stored and shared electronically between the patient's medical team with ease. Once the data is built up, AI will create advances in automated tissue adequacy assessment and diagnosis. Aquyre's CelTivity™  system will change the current standard in terms of patient care, hospital workflow and overall costs, according to the company. Aquyre has offices in Cambridge, Massachusetts, and Paris, France.

"With our cellular imaging technology, it takes about two minutes from live tissue to data and digital image for review by the medical expert.  The funding will allow us to accelerate the commercialization of our system in the US," said Bertrand Le Conte de Poly, CEO of Aquyre Biosciences.

"The need for quick, real-time data is critical in cancer detection and diagnosis.  Biopsy assessment can take up to seven days with the current technology and surgical procedures for cancer detection, and they don't produce results in real time.  Aquyre's Biopsy Scanner transforms the entire process," said Mark Goldwasser, CEO of Ceros Financial Services. 

Goldwasser said that Ceros is targeting to raise $100 million over the next twelve months for investment in early-stage medical technology and medical device companies.  This spring, the firm co-led $96 million for Memic Innovative Surgery to support commercialization of Memic's Hominis® robotic-assisted platform. The Hominis system is the first and only FDA-authorized surgical robotic platform featuring miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation.  The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon's arms.

Ceros has completed about $77 million in transactions in the past year.  In addition to Aquyre and Memic, investments include OrthoSensor, which has developed a sensor-assisted device used during knee surgery that sends real-time data to an operating room monitor, assisting surgeons' decision-making; DermoSensor, which designs non-invasive tools that use machine learning and spectroscopy to evaluate skin lesions for cancer; and Insightec, which uses guided focused ultrasound equipment for non-invasive brain surgery.

"We believe the medical technology sector holds great potential.  Our focus will continue on emerging companies working on innovative new technologies which could prove to be disruptive and transformative," Goldwasser said.

About Ceros Financial Services, Inc.

Ceros Financial Services, Inc. Member FINRA/SIPC (www.cerosfs.com) offers a comprehensive asset management and mutual fund suite for financial advisors.  Ceros services include RIA custody, hybrid advisors, corporate RIA, mutual fund advisory and distribution, and an outsourced trade desk.  In addition, Ceros Capital Markets, a division of Ceros Financial, is a digital and traditional platform for the distribution of primary offerings in medical devices and secondaries in unicorns via Special Purpose Vehicles (SPVs).

Investing in the securities markets involves risk, including loss of principal. Private Placements are not appropriate for all investors. Most if not all investments in Private Placements are illiquid and many such investments are speculative in nature. Investing in a Private Placement can result in a significant risk of loss of principal. Risk factors for private offerings are listed in the Private Placement Memorandum; and should be read carefully prior to investing.

SOURCE Ceros Financial Services